Atlas of Genetics and Cytogenetics in Oncology and Haematology


Home   Genes    Leukemias    Solid Tumours    Cancer-Prone    Deep Insight    Case Reports    Journals   Portal    Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA
    

The Fas - Fas Ligand apoptotic pathway

Pierre Bobé

UPR CNRS 9045, Institut André Lwoff,
7 rue G Môquet, 94807 Villejuif, France
E-mail : bobe@infobiogen.fr

February 2002

 

Background on apoptosis

Cell death can be achieved by two fundamentally different mechanisms, apoptosis and necrosis. Apoptosis is characterized by several morphological features that include condensation of nuclei and internucleosomal degradation of DNA, cell membrane blebbing, and formation of apoptotic bodies. By contrast, necrosis is recognized by swelling of the cell and organelles, followed by disintegration of the cell and the release of cytoplasmic material. Although the necrotic signalling pathway remains largely uncharacterized at the molecular level, apoptosis is known to be dependent on a family of intracellular cysteine proteases, called CASPASES (Cysteine Aspartate Specific ProteASEs). Caspases (Nicholson DW, 1999) are initially synthesized as inactive cytosolic proteases (proenzymes) which have a p20 and a p10 domain that, in response to apoptotic stimulation, are cleaved to form the active enzyme. Active caspases then cleave other caspases, Bcl-2 family members, or act on various nuclear substrates, such as lamins and caspase-activated DNase (CAD), finally leading to apoptosis. Caspases contain a cysteine residue within the active site, and which cleave their substrate exclusively after an aspartic acid residue, a sequence of 3 amino acids before aspartate determines substrate specificity. Caspases can be divided into inflammatory caspases (-1, -4, -5, -11, -12, -13 and -14), which cleave and activate proinflammatory cytokines, and proapoptotic caspases, which cleave and activate proapoptotic substrates. Proapoptotic caspases comprise initiator caspases (-2, -8, -9 and -10), which, in turn, cleave and activate effector or executioner caspases (-3, -6 and -7).

Apoptosis can be induced either from the cell surface, by ligand-dependent triggering of death receptors (e.g: CD95/Fas; TNF-R1; TNF related apoptosis-inducing ligand receptor 1, TRAIL-R1/DR4 and TRAIL-R2/DR5), or by the stimulation of intracellular receptor proteins, such as apoptotic protease-activating factor 1 (Apaf-1), which is activated by its ligand cytochrome c once it is released from damaged mitochondria (Ranger et al., 2001). Both systems transmit apoptotic signals through protein-protein interactions that are mediated by motifs called the death domain (DD), the death effector domain (DED) and the caspase recruitment domain (CARD).

Death domains (DD) are 80-100 residue long motifs found both in cytoplasmic proteins (FADD: Fas-associated protein with Death Domain; TRADD: TNF Receptor-associated protein with Death Domain; and RIP: Receptor Interacting Protein) and in transmembrane proteins including members of the TNF-receptor superfamily, like Fas, TNF-R1, TRAIL-R1/DR4 and TRAIL-R2/DR5. DD serve as recruiting modules through their ability to heterodimerize with the DD of distinct proteins, including adaptor proteins such as FADD, TRADD and RIP.

Death-effector domain (DED) is a protein interaction domain found in inactive procaspases (-8 and -10) and proteins that regulate caspase activation in the apoptosis cascade. The DED recruits procaspases into complexes with members of the TNF-receptor superfamily. This recruitment is mediated by a homotypic interaction between the procaspase DED and a second DED in a FADD adaptor molecule that is directly associated with activated members of the TNF-receptor superfamily. Complex formation allows transprocessing of procaspase to the active form. This, in turn, activates downstream caspases and initiates apoptosis. Caspases-8 (FLICE)- and -10 (FLICE 2)-inhibitory proteins were identified in virus and human and designated v-FLIP and c-FLIP, respectively (Thome M et al., 1997; Irmler et al., 1997). The human FLIP was also cloned by several labs independently and termed Casper, I-FLICE, FLAME-1, CASH and CLARP. FLIP contains two death DEDs and a caspase-like domain. FLIP interacts with adapter protein FADD and caspase-8 and -10, and potently inhibits apoptosis induced by all known death receptors. Several splicing isoforms of c-FLIP occur, two of which are expressed as proteins in vivo: short FLIP (c-FLIPS) of 26 kDa and long FLIP (c-FLIPL) of 55 kDa. c-FLIPS consist essentially of two repeats of a DED and c-FLIPL contains a carboxy terminal inactive caspase-like domain which confers on the molecule an overall structural homology with caspase-8 and caspase-10 (Thome M and Tschopp J, Nature Reviews Immunology, 2001).

Caspase recruitment domains (CARD) are 90-100 amino acids long motifs. CARD mediates the association of adaptor proteins (RAIDD, Apaf-1) and procaspases (-2 and -9), through heterodimerization of the respective CARD, recruiting procaspases to upstream signaling complexes and allowing autoactivation.

The Fas- Fas Ligand pathway

Although Fas - Fas Ligand (FasL) interactions are not limited to the immune system, it is where most of their functional studies have originated.Apoptosis in the immune system is a fundamental process regulating lymphocyte maturation, receptor repertoire selection and homeostasis. In the immune system, apoptosis occurs during T and B lymphocyte repertoire selection and cytolytic T-cell-mediated killing (Fig.1).

Figure 1

Apoptosis also plays an essential role in the removal of excess T- and B-cells as part of the mechanisms maintaining cellular homeostasis during immune responses. Defects in this process lead to the accumulation of potentially autoreactive T- and B-cells. A subset of members of the TNF-R superfamily is involved in death transducing signals in cells of the immune system. This family is constantly expanding and includes receptors for TNF-a, lymphotoxin-a, TNF related apoptosis-inducing ligand (TRAIL) and FasL. Members of this TNF-R1 family contain one to five extracellular cysteine-rich domains, and in their cytoplasmic tail a death domain (DD) essential for transduction of the apoptotic signal. Fas (CD95 or Apo-1) is one such family member (Itoh et al., 1991) and has a major role in the immune system. The Fas protein is a type 1 transmembrane glycoprotein with three extra-cellular cysteine-rich domains (CRD). Fas is ubiquitously expressed on a variety of normal cells, including lymphocytes and hepatocytes. It expression can be increased by the activation of lymphocytes but also by cytokines such as interferon-g and TNF. It is a type I transmembrane glycoprotein of relative molecular mass ~ 45,000 (molecule with 320 amino-acid residues, 157 amino acid extracellular domain), but alternative splicing can result in a soluble form termed decoy receptor 3 (DcR3), that binds FasL and inhibits FasL-induced apoptosis. Fas-mediated apoptosis is triggered by its ligand, FasL (Suda et al., 1993), which is expressed in a far more restricted way than the receptor, including activated T-cells, NK (natural killer) cells. On other hand, it has long been know that certain sites in the body, for example, the eye, the testes and the brain are "privileged". They are protected from attack by the immune system. Many factors are involved in immune privilege, such as tight junctions between the cells of the tissue, little expression of class I histocompatibility molecules, and expression of FasL. For instance, the corneal epithelium and the retina of the eye, Sertoli cells of the testis and the trophoblast of the placenta express FasL. Indeed, the placenta also enjoys immune privilege. It is almost as foreign to the mother as a kidney transplant from her husband would be, but unlike the kidney, she will not reject it. When threatened by a cytotoxic T cell, cells from "privileged" sites avoid being killed by forcing the T lymphocyte to commit suicide by apoptosis (Green and Ferguson, 2001). Some tumors also express FasL, which has been suggested as a mechanism to escape immune surveillance. FasL is a TNF-related type II transmembrane molecule of ~ 40 kDa but can also be cleaved from the membrane by a metalloprotease, while soluble human FasL can induce apoptosis, soluble mouse FasL cannot.

Both Fas and FasL are predicted to form trimers, with extra-cellular cysteine-rich domain (CRD) 2 and CRD3 forming the major contact surfaces for FasL. Recently, it has been found that Fas and TNF-R share a self-association domain in CRD1, termed the "pre-ligand assembly domain" (PLAD) and formation of preassociated receptor complexes is necessary for TNF-R and Fas signaling (Siegel et al., 2000). Following Fas - FasL ligation a complex of proteins associates with activated Fas (Fig.2).

Figure 2

This death-inducing signalling complex (DISC) forms within seconds of receptor engagement. First, the adaptor FADD binds via its own DD to the DD in Fas. FADD also carries a DED, and, again by homologous interaction, recruits the DED-containing procaspase-8 into the DISC. Next, procaspase-8 is activated proteolytically and active caspase-8 is released from the DISC into the cytoplasm in the form of a heterotetramer of two small subunits (~ p10) and two large subunits (~ p20). Recently two different pathways of Fas-mediated apoptosis have been identified. Fas-mediated apoptosis in type I cells (lymphoid cells) is initiated by large amounts of active caspase-8 formed at the DISC followed by direct cleavage of procaspase-3. Activated caspase-3 cleaves a variety of substrates, including DNA repair enzymes, such as poly-ADP ribose polymerase and DNA protein kinase; cellular and nuclear structural proteins, including nuclear mitotic apparatus, lamins, and actin; and endonucleases (Sakahira et al., 1998), such as caspase-activated deoxyribonuclease (CAD) inhibitor (ICAD) and many other cellular constituents. Moreover, caspase-3 has the ability to activate other caspases, such as procaspase-6 and -7, resulting in an amplification of cellular destruction. In contrast, in type II cells (hepatocytes) very little DISC and small amounts of active caspase-8 are formed, so the caspase cascade has to be amplified by activating the apoptosome, the second initiator complex of apoptosis. Then, Caspase-8 cuts the Bcl-2 family member Bid; truncated Bid induced insertion of BAX into mitochondrial membrane and mitochondria release pro-apoptotic molecules such as cytochrome c and smac/diablo. Together with the apoptosis protease-activating factor Apaf-1, procaspase-9 in the cytoplasm, these molecules form the apoptosome. Caspase-9 activates further downstream procaspases-3 (Fig. 2). Bid-deficient mice are resistant to Fas-induced hepatocellular apoptosis (Yin et al., 1999).

Fas-mediated apoptosis may also be activated by the recruitment of molecules other than FADD. The DD in Fas undergo homotypic interaction with the DD of receptor interacting protein (RIP) kinase (Kelliher et al., 1998). RIP, in turn, binds the adapter molecule RAIDD (RIP-associated ICH-1/CED-3-homologous protein with a death domain) to recruit and activate procaspase-2 via homotypic interaction of their CARD. Moreover, ligation of Fas leads to activation of the c-Jun N-terminal kinase (JNK) pathway in many cell types. Fas was reported to engage the JNK pathway via Death Domain associated protein (Daxx)-mediated activation of Ask1/MKK5. Overexpressed Daxx was shown to potentiate anti-Fas Ab-induced apoptosis and JNK activation.

Diseases involving the Fas - Fas Ligand pathway:

  • In tumors

    CD8+ cytotoxic T lymphocytes (CTL) and CD4+ T cells play crucial roles in host defense against malignancies. However, it is also becoming clearer that neoplastic cells may evade cell-mediated immunity at multiple levels of the effector/target interaction which, consequently, may impact the metastatic process. Malignant melanoma accounts for most of the increasing mortality from skin cancer. Melanoma cells were found to express FasL. In metastatic lesions, Fas expressing T-cell infiltrates were proximal to FasL expressing tumor-cells. Binding of tumor-associated FasL to its cognate receptor Fas on tumor infiltrating T-cells, produces apoptosis, in the susceptible target T-cells (Hahne et al., 1996). In vitro, apoptosis of Fas-sensitive target cells occurred on incubation with melanoma tumor cells; and in vivo, injection of FasL expressing mouse melanoma cells in mice led to rapid tumor formation. In contrast, tumorigenesis was delayed in Fas deficient mice in which immune effector cells cannot be killed by FasL. Thus FasL may contribute to the immune privilege of tumors (Ferguson and Griffith, 1997).

  • Genetic defects in the Fas - Fas Ligand pathway: lpr mice

    Dysregulation of apoptosis, particularly in the Fas - FasL pathway, is considered to be involved in the pathogenesis of autoimmune diseases such as systemic lupus erythematosus (SLE). Watanabe-Fukunaga et al., (1992) demonstrated that MRL/lpr mice carrying the lymphoproliferation (lpr) mutation have defects in the Fas gene. The autosomal recessive lpr mutation of the murine MRL strain is associated with the development of massive lymphadenopathy and an autoimmune syndrome resembling human SLE and rheumatoid arthritis (RA). This mutation corresponds to a marked decrease of the expression of the Fas receptor, as a consequence of an ETn retrotransposon insertion into the second intron of the gene (Wu et al., 1993; Kobayashi et al., 1993; Chu et al., 1993), and results in the accumulation of a large number of non-malignant CD4-CD8- T lymphocytes in lymph nodes and spleen (Morse et al., 1982; Budd et al., 1985). The lpr autoimmune syndrome of glomerulonephritis, vasculitis, and arthritis is regularly manifested at an early age in the MRL mouse background, but by contrast, the same mutation causes essentially no autoimmune disease when bred onto the C57BL/6 background. On other backgrounds, such as C3H, the onset is delayed and the autoimmune manifestations are milder than in MRL mice suggesting that modifier genes make a major contribution to the disease phenotype (Izui et al., 1984; Davidson et al., 1984; Morse et al., 1985).

    Peripheral activated T cells from lpr/lpr mutant mice that express a reduced number of Fas receptors have a defect in T-cell receptor (TCR)-induced apoptosis. Dhein et al., propose that TCR-induced apoptosis in activated T cells occurs through a FasL-mediated autocrine suicide (Dhein et al., 1995). Their results suggested a mechanism for suppression of the immune response and for peripheral tolerance by T-cell deletion. Brunner et al. in 1995 provided supporting evidence by showing that the interaction between Fas and FasL inhibits activation-induced apoptosis (AICD). Because T-cell receptor ligation can induce apoptosis in a single T hybridoma cell, they suggested that the Fas - FasL interaction could induce cell death in a cell-autonomous manner. Likewise, Ju et al in 1995 showed that the interaction between Fas and FasL accounts for activation-induced T-cell death.

    In the autoimmune-prone MRL/lpr mice, as a consequence of the defect in the AICD, CD4-CD8- double-negative (DN) T lymphocytes accumulating in this strain overexpress the FasL. Owing to the massive overexpression of the FasL, the DN T lymphocytes exhibited cytotoxic activity against tumor cells bearing spontaneously, or after transfection, the Fas molecule (Chu et al., 1995; Watanabe et al., 1995) or against H-2 compatible or incompatible Fas expressing thymocytes or lipopolysaccharide-induced blasts (Benihoud et al., 1997). Therefore, the overexpression of FasL by activated MRL/lpr lymphocytes could be responsible for a chronic, non-antigen-specific autoimmune attack on organs expressing low levels of the Fas receptor. Indeed, the lpr mutation is leaky, and low, but non-negligible, levels of transcription (Wu et al., 1993; Kobayashi et al., 1993) and translation (Mariani et al., 1994) of the wild-type Fas molecule have been reported in this strain, as illustrated by the observation of the existence of non-negligible amounts of Fas on MRL/lpr hepatocytes, in contrast to hepatocytes from mice rendered completely Fas-deficient by gene targeting (Adachi et al., 1995).

  • Genetic defects in the Fas - Fas Ligand pathway: in humans

    Rieux-Laucat et al in 1995 analyzed expression of the FAS receptor and its function in 3 children including 2 siblings, with a lymphoproliferative syndrome, 2 of whom also had autoimmune disorders. A large deletion in the FAS gene and no detectable cell surface expression characterized the most affected patient. Clinical manifestations in the 2 sibs were less severe. A deletion within the intracytoplasmic domain of FAS was detected and FAS-mediated apoptosis was impaired. On other hand, 5 unrelated children were described (Fisher et al., 1995) with a rare autoimmune lymphoproliferative syndrome (ALPS) characterized by autoimmune phenomena, massive nonmalignant lymphadenopathy and expanded populations of CD4-CD8- T lymphocytes which evoke a genetic defect in the AICD mechanisms. Each child had defective FAS-mediated T lymphocyte apoptosis associated with a unique, deleterious FAS gene mutation. One mutation appeared to cause a simple loss of function; however, 4 others had a dominant-negative phenotype when coexpressed with normal FAS. Thus, FAS is the cause of this disorder of lymphocyte homeostasis and peripheral self-tolerance. ALPS resemble to lpr/gld disease in the mouse (gld mice bear mutated genes for FasL). In both the mouse and the human, hypergammaglobulinemia is a prominent feature of the disease. In the mouse, autoantibodies, especially antinuclear antibodies, form immune complexes that are deposited in the kidney to cause glomerulonephritis. Autoantibodies were seen (Fisher et al., 1995) in only 2 of the ALPS patients, and antinuclear antibodies were not observed. However, one patient developed glomerulonephritis, and all 5 children had autoimmune cytopenias and rashes. In contrast to the mouse lpr mutation, which is recessive, simple recessive inheritance was ruled out in all 5 ALPS patients studied because all showed 1 mutated FAS allele and 1 normal allele. In each case, the novel FAS mutation in the affected child was inherited from a carrier parent. Parental genetic mosaicism was observed in the mother of one patient in whom a normal and a mutant FAS allele were observed and whose apoptosis defect was less marked than that of her affected son. Fisher, suggested that modifier genes make a major contribution to the disease phenotype and account for the fact that the heterozygous parent was unaffected. In the lpr mouse, the typical autoimmune syndrome is regularly manifested at an early age in the MRL mouse background, but by contrast, the same mutation causes essentially no autoimmune disease when bred onto the C57BL/6 and C3H background. Thus, it is not surprising that in an outbred human population, individuals bearing the same FAS gene mutation may have dramatically different phenotypes. Defining the additional segregating gene(s) that causes expression of the full manifestations of ALPS in the presence of FAS dysfunction will be important for understanding how FAS participates in immune regulation.

  • Fas-mediated liver diseases

    In normal mice, hepatocytes, which are Fas-expressing cells, are highly sensitive to Fas-mediated apoptosis initiated in vitro by an anti-Fas monoclonal antibody. In vivo injection of this antibody leads to massive apoptosis in the liver with death of the animal within a few hours (Ogasawara et al., 1993). These findings suggest that the Fas antigen is important in programmed cell death in the liver, and may be involved in fulminant hepatitis in some cases. The role of T lymphocytes in hepatocyte destruction during the course of acute viral hepatitis has been suggested based on animal models expressing human hepatitis B virus transgenes (Ando et al., 1993; Takahashi et al., 1995). In patients with acute hepatitis B, a polyclonal and multispecific CTL response to viral polymerase was observed (Rehermann et al., 1995). These CTL activities could be mediated, at least in part, by Fas-induced apoptosis. Indeed, a significant increase in Fas mRNA has been detected in the liver during the course of acute liver failure in hepatitis B (Galle et al., 1995) and chronic hepatitis C (Hiramatsu et al., 1994) with strong FasL expression on infiltrating lymphocytes (Galle et al., 1995).

    Bobé et al. (1997) investigated the consequences of the in vivo interaction of lymphocytes overexpressing the FasL with hepatocytes expressing normal amounts of Fas. These experimental conditions were met by creating hematopoietic chimeras by grafting wild-type MRL+/+ with MRL/lpr lymphoid cells which overexpress FasL (MRL/lpr ->  +/+ chimeras). In parallel with elevated serum transaminase levels, histological examination of MRL/lpr ->  +/+ chimeras livers showed infiltrations of activated lymphocytes (polyclonal population of FasL-expressing T lymphocytes) in periportal areas and intralobular foci, with hepatocytes undergoing apoptosis in their vicinity.

  • Fas-mediated rheumatoid diseases

    Synoviocytes are Fas-expressing cells, particularly in arthritic mice (Ito et al., 1997) and RA patients (Nakajima et al., 1995). Indeed, these cells are sensitive in vitro to anti-Fas monoclonal antibody-induced apoptosis (Hasunuma et al., 1996; Sakai et al., 1998) particularly in RA synovium (Asahara et al., 1996). The Fas receptor has also been detected on human chondrocytes (Kim et al., 1999) and osteoblasts (Nakashima et al., 1998). Furthermore, T cells infiltrating the RA affected joints express FasL (Hoa et al., 1996; Sumida et al., 1997). Soluble Fas receptor, which may inhibit the regulation of these activated T lymphocytes by AICD, has also been observed in the synovial fluid of the inflamed joints of RA patients (Hasunuma et al., 1997). These observations suggest that at least two mechanisms may be implicated in RA damage: first, impaired clearance of activated T cells due to a defective step in the Fas-mediated apoptotic pathway; second, overexpression of FasL on synovium-infiltrating lymphocytes. To test this latter hypothesis, Bonardelle et al. (2001) evaluated the consequences of an in vivo interaction between long-lived MRL/lpr lymphocytes overexpressing FasL and Fas-expressing synoviocytes of the wild-type MRL strain. These experimental conditions were met in hematopoietic chimeras created by grafting lethally irradiated wild-type MRL+/+ with MRL/lpr lymphoid cells (MRL/lpr ->  +/+ chimeras). MRL/lpr ->  +/+ chimeras developed severe rheumatoid disease, with synovitis, pannus, bone erosion and periostitis within a few weeks post grafting.

    In conclusion, there is increasing evidence that derangement of the usually highly controlled apoptotic program is the underlying cause of various diseases.

    Bibliography

    Targeted mutation in the Fas gene causes hyperplasia in peripheral lymphoid organs and liver.
    Adachi M, Suematsu S, Kondo T, Ogasawara J, Tanaka T, Yoshida N, Nagata S
    Nature genetics. 1995 ; 11 (3) : 294-300.
    PMID 7581453
     
    Mechanisms of class I restricted immunopathology. A transgenic mouse model of fulminant hepatitis.
    Ando K, Moriyama T, Guidotti LG, Wirth S, Schreiber RD, Schlicht HJ, Huang SN, Chisari FV
    The Journal of experimental medicine. 1993 ; 178 (5) : 1541-1554.
    PMID 8228807
     
    Expression of Fas antigen and Fas ligand in the rheumatoid synovial tissue.
    Asahara H, Hasumuna T, Kobata T, Yagita H, Okumura K, Inoue H, Gay S, Sumida T, Nishioka K
    Clinical immunology and immunopathology. 1996 ; 81 (1) : 27-34.
    PMID 8808638
     
    MRL/lpr CD4- CD8- and CD8+ T cells, respectively, mediate Fas-dependent and perforin cytotoxic pathways.
    Benihoud K, Bonardelle D, Bobé P, Kiger N
    European journal of immunology. 1997 ; 27 (2) : 415-420.
    PMID 9045912
     
    Fas-mediated liver damage in MRL hemopoietic chimeras undergoing lpr-mediated graft-versus-host disease.
    Bobé P, Bonardelle D, Reynès M, Godeau F, Mahiou J, Joulin V, Kiger N
    Journal of immunology (Baltimore, Md. : 1950). 1997 ; 159 (9) : 4197-4204.
    PMID 9379013
     
    Inflammatory arthropathy in MRL hematopoietic chimeras undergoing Fas mediated graft-versus-host syndrome.
    Bonardelle D, Bobé P, Reynès M, Amouroux J, Tricottet V, Godeau F, Kiger N
    The Journal of rheumatology. 2001 ; 28 (5) : 956-961.
    PMID 11361222
     
    Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas.
    Brunner T, Mogil RJ, LaFace D, Yoo NJ, Mahboubi A, Echeverri F, Martin SJ, Force WR, Lynch DH, Ware CF
    Nature. 1995 ; 373 (6513) : 441-444.
    PMID 7530336
     
    Growth and differentiation in vitro of the accumulating Lyt-2-/L3T4- subset in lpr mice.
    Budd RC, MacDonald HR, Lowenthal JW, Davignon JL, Izui S, Cerottini JC
    Journal of immunology (Baltimore, Md. : 1950). 1985 ; 135 (6) : 3704-3711.
    PMID 3934265
     
    The defect in Fas mRNA expression in MRL/lpr mice is associated with insertion of the retrotransposon, ETn.
    Chu JL, Drappa J, Parnassa A, Elkon KB
    The Journal of experimental medicine. 1993 ; 178 (2) : 723-730.
    PMID 7688033
     
    Massive upregulation of the Fas ligand in lpr and gld mice: implications for Fas regulation and the graft-versus-host disease-like wasting syndrome.
    Chu JL, Ramos P, Rosendorff A, Nikolić-Zugić J, Lacy E, Matsuzawa A, Elkon KB
    The Journal of experimental medicine. 1995 ; 181 (1) : 393-398.
    PMID 7528774
     
    Dissociation of severe lupus-like disease from polyclonal B cell activation and IL 2 deficiency in C3H-lpr/lpr mice.
    Davidson WF, Roths JB, Holmes KL, Rudikoff E, Morse HC 3rd
    Journal of immunology (Baltimore, Md. : 1950). 1984 ; 133 (2) : 1048-1056.
    PMID 6610701
     
    Autocrine T-cell suicide mediated by APO-1/(Fas/CD95)
    Dhein J, Walczak H, Bäumler C, Debatin KM, Krammer PH
    Nature. 1995 ; 373 (6513) : 438-441.
    PMID 7530335
     
    A vision of cell death: insights into immune privilege.
    Ferguson TA, Griffith TS
    Immunological reviews. 1997 ; 156 : 167-184.
    PMID 9176707
     
    Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage.
    Galle PR, Hofmann WJ, Walczak H, Schaller H, Otto G, Stremmel W, Krammer PH, Runkel L
    The Journal of experimental medicine. 1995 ; 182 (5) : 1223-1230.
    PMID 7595193
     
    The role of Fas ligand in immune privilege.
    Green DR, Ferguson TA
    Nature reviews. Molecular cell biology. 2001 ; 2 (12) : 917-924.
    PMID 11733771
     
    Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape.
    Hahne M, Rimoldi D, Schröter M, Romero P, Schreier M, French LE, Schneider P, Bornand T, Fontana A, Lienard D, Cerottini J, Tschopp J
    Science (New York, N.Y.). 1996 ; 274 (5291) : 1363-1366.
    PMID 8910274
     
    Induction of Fas-dependent apoptosis in synovial infiltrating cells in rheumatoid arthritis.
    Hasunuma T, Hoa TT, Aono H, Asahara H, Yonehara S, Yamamoto K, Sumida T, Gay S, Nishioka K
    International immunology. 1996 ; 8 (10) : 1595-1602.
    PMID 8921439
     
    Accumulation of soluble Fas in inflamed joints of patients with rheumatoid arthritis.
    Hasunuma T, Kayagaki N, Asahara H, Motokawa S, Kobata T, Yagita H, Aono H, Sumida T, Okumura K, Nishioka K
    Arthritis and rheumatism. 1997 ; 40 (1) : 80-86.
    PMID 9008603
     
    Immunohistochemical detection of Fas antigen in liver tissue of patients with chronic hepatitis C.
    Hiramatsu N, Hayashi N, Katayama K, Mochizuki K, Kawanishi Y, Kasahara A, Fusamoto H, Kamada T
    Hepatology (Baltimore, Md.). 1994 ; 19 (6) : 1354-1359.
    PMID 7514559
     
    Novel mechanisms of selective apoptosis in synovial T cells of patients with rheumatoid arthritis.
    Hoa TT, Hasunuma T, Aono H, Masuko K, Kobata T, Yamamoto K, Sumida T, Nishioka K
    The Journal of rheumatology. 1996 ; 23 (8) : 1332-1337.
    PMID 8856610
     
    Rheumatic diseases in an MRL strain of mice with a deficit in the functional Fas ligand.
    Ito MR, Terasaki S, Itoh J, Katoh H, Yonehara S, Nose M
    Arthritis and rheumatism. 1997 ; 40 (6) : 1054-1063.
    PMID 9182916
     
    The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis.
    Itoh N, Yonehara S, Ishii A, Yonehara M, Mizushima S, Sameshima M, Hase A, Seto Y, Nagata S
    Cell. 1991 ; 66 (2) : 233-243.
    PMID 1713127
     
    Inhibition of death receptor signals by cellular FLIP.
    Irmler M, Thome M, Hahne M, Schneider P, Hofmann K, Steiner V, Bodmer JL, Schröter M, Burns K, Mattmann C, Rimoldi D, French LE, Tschopp J
    Nature. 1997 ; 388 (6638) : 190-195.
    PMID 9217161
     
    Induction of various autoantibodies by mutant gene lpr in several strains of mice.
    Izui S, Kelley VE, Masuda K, Yoshida H, Roths JB, Murphy ED
    Journal of immunology (Baltimore, Md. : 1950). 1984 ; 133 (1) : 227-233.
    PMID 6609979
     
    Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation.
    Ju ST, Panka DJ, Cui H, Ettinger R, el-Khatib M, Sherr DH, Stanger BZ, Marshak-Rothstein A
    Nature. 1995 ; 373 (6513) : 444-448.
    PMID 7530337
     
    The death domain kinase RIP mediates the TNF-induced NF-kappaB signal.
    Kelliher MA, Grimm S, Ishida Y, Kuo F, Stanger BZ, Leder P
    Immunity. 1998 ; 8 (3) : 297-303.
    PMID 9529147
     
    Apoptotic chondrocyte death in rheumatoid arthritis.
    Kim HA, Song YW
    Arthritis and rheumatism. 1999 ; 42 (7) : 1528-1537.
    PMID 10403282
     
    Transcriptional repression and differential splicing of Fas mRNA by early transposon (ETn) insertion in autoimmune lpr mice.
    Kobayashi S, Hirano T, Kakinuma M, Uede T
    Biochemical and biophysical research communications. 1993 ; 191 (2) : 617-624.
    PMID 7681668
     
    The APO-1/Fas (CD95) receptor is expressed in homozygous MRL/lpr mice.
    Mariani SM, Matiba B, Armandola EA, Krammer PH
    European journal of immunology. 1994 ; 24 (12) : 3119-3123.
    PMID 7528670
     
    Abnormalities induced by the mutant gene Ipr: expansion of a unique lymphocyte subset.
    Morse HC 3rd, Davidson WF, Yetter RA, Murphy ED, Roths JB, Coffman RL
    Journal of immunology (Baltimore, Md. : 1950). 1982 ; 129 (6) : 2612-2615.
    PMID 6815273
     
    Abnormalities induced by the mutant gene, lpr. Patterns of disease and expression of murine leukemia viruses in SJL/J mice homozygous and heterozygous for lpr.
    Morse HC 3rd, Roths JB, Davidson WF, Langdon WY, Fredrickson TN, Hartley JW
    The Journal of experimental medicine. 1985 ; 161 (3) : 602-616.
    PMID 2982991
     
    Apoptosis and functional Fas antigen in rheumatoid arthritis synoviocytes.
    Nakajima T, Aono H, Hasunuma T, Yamamoto K, Shirai T, Hirohata K, Nishioka K
    Arthritis and rheumatism. 1995 ; 38 (4) : 485-491.
    PMID 7536416
     
    Inhibitory effect of glucocorticoid for osteoblast apoptosis induced by activated peripheral blood mononuclear cells.
    Nakashima T, Sasaki H, Tsuboi M, Kawakami A, Fujiyama K, Kiriyama T, Eguchi K, Ichikawa M, Nagataki S
    Endocrinology. 1998 ; 139 (4) : 2032-2040.
    PMID 9528991
     
    Caspase structure, proteolytic substrates, and function during apoptotic cell death.
    Nicholson DW
    Cell death and differentiation. 1999 ; 6 (11) : 1028-1042.
    PMID 10578171
     
    Lethal effect of the anti-Fas antibody in mice.
    Ogasawara J, Watanabe-Fukunaga R, Adachi M, Matsuzawa A, Kasugai T, Kitamura Y, Itoh N, Suda T, Nagata S
    Nature. 1993 ; 364 (6440) : 806-809.
    PMID 7689176
     
    Mouse models of cell death.
    Ranger AM, Malynn BA, Korsmeyer SJ
    Nature genetics. 2001 ; 28 (2) : 113-118.
    PMID 11381252
     
    The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis.
    Rehermann B, Fowler P, Sidney J, Person J, Redeker A, Brown M, Moss B, Sette A, Chisari FV
    The Journal of experimental medicine. 1995 ; 181 (3) : 1047-1058.
    PMID 7532675
     
    Cleavage of CAD inhibitor in CAD activation and DNA degradation during apoptosis.
    Sakahira H, Enari M, Nagata S
    Nature. 1998 ; 391 (6662) : 96-99.
    PMID 9422513
     
    Potential withdrawal of rheumatoid synovium by the induction of apoptosis using a novel in vivo model of rheumatoid arthritis.
    Sakai K, Matsuno H, Morita I, Nezuka T, Tsuji H, Shirai T, Yonehara S, Hasunuma T, Nishioka K
    Arthritis and rheumatism. 1998 ; 41 (7) : 1251-1257.
    PMID 9663483
     
    Fas preassociation required for apoptosis signaling and dominant inhibition by pathogenic mutations.
    Siegel RM, Frederiksen JK, Zacharias DA, Chan FK, Johnson M, Lynch D, Tsien RY, Lenardo MJ
    Science (New York, N.Y.). 2000 ; 288 (5475) : 2354-2357.
    PMID 10875918
     
    Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family.
    Suda T, Takahashi T, Golstein P, Nagata S
    Cell. 1993 ; 75 (6) : 1169-1178.
    PMID 7505205
     
    T cell receptor of Fas-sensitive T cells in rheumatoid synovium.
    Sumida T, Hoa TT, Asahara H, Hasunuma T, Nishioka K
    Journal of immunology (Baltimore, Md. : 1950). 1997 ; 158 (4) : 1965-1970.
    PMID 9029139
     
    Acute hepatitis in rats expressing human hepatitis B virus transgenes.
    Takahashi H, Fujimoto J, Hanada S, Isselbacher KJ
    Proceedings of the National Academy of Sciences of the United States of America. 1995 ; 92 (5) : 1470-1474.
    PMID 7878002
     
    Regulation of lymphocyte proliferation and death by FLIP.
    Thome M, Tschopp J
    Nature reviews. Immunology. 2001 ; 1 (1) : 50-58.
    PMID 11905814
     
    Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors.
    Thome M, Schneider P, Hofmann K, Fickenscher H, Meinl E, Neipel F, Mattmann C, Burns K, Bodmer JL, Schröter M, Scaffidi C, Krammer PH, Peter ME, Tschopp J
    Nature. 1997 ; 386 (6624) : 517-521.
    PMID 9087414
     
    Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis.
    Watanabe-Fukunaga R, Brannan CI, Copeland NG, Jenkins NA, Nagata S
    Nature. 1992 ; 356 (6367) : 314-317.
    PMID 1372394
     
    Constitutive activation of the Fas ligand gene in mouse lymphoproliferative disorders.
    Watanabe D, Suda T, Hashimoto H, Nagata S
    The EMBO journal. 1995 ; 14 (1) : 12-18.
    PMID 7530197
     
    Autoimmune disease in mice due to integration of an endogenous retrovirus in an apoptosis gene.
    Wu J, Zhou T, He J, Mountz JD
    The Journal of experimental medicine. 1993 ; 178 (2) : 461-468.
    PMID 7688023
     
    Bid-deficient mice are resistant to Fas-induced hepatocellular apoptosis.
    Yin XM, Wang K, Gross A, Zhao Y, Zinkel S, Klocke B, Roth KA, Korsmeyer SJ
    Nature. 1999 ; 400 (6747) : 886-891.
    PMID 10476969
     
    Written2002-01Pierre Bobé
    André Lwoff, CNRS UPR 9045, Laboratoire d'Oncologie Virale, 7, rue Guy Môquet, 94801 Villejuif, France

    Citation

    This paper should be referenced as such :
    Bobé P
    The Fas - Fas Ligand apoptotic pathwa
    Atlas Genet Cytogenet Oncol Haematol. in press
    On line version : http://AtlasGeneticsOncology.org/Deep/Fas-FasLigandID20040.htm

    © Atlas of Genetics and Cytogenetics in Oncology and Haematology
    indexed on : Tue Mar 14 13:58:00 CET 2017


    Home   Genes    Leukemias    Solid Tumours    Cancer-Prone    Deep Insight    Case Reports    Journals   Portal    Teaching   

    X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

    For comments and suggestions or contributions, please contact us

    jlhuret@AtlasGeneticsOncology.org.